Nebula Genomics, Blockchain firm, has decided to collaborate with EMD Serono, the North American Merck KGaA’s biopharmaceutical business — which is also considered the oldest firm in the pharmaceutical arena.
Back in 2017, Professor George Church, a renowned geneticist, colluded with his Harvard colleagues Kamal Obbad and Dennis Grishin to build a genome-sequencing data blockchain-powered platform known as Nebula.
Apart from individuals being able to control their sensitive and unique data as well as preserve its privacy, the platform also uses blockchain technology to lower genome-sequencing costs and incentivize genomic data sharing and generation.
The agreement represents Nebula’s initial attempt to realize a sponsored genome sequencing model. Through the collaboration with EDM Serono, the firm hopes to support various research and development of new medication ventures as the anonymized genomic data network will be easily accessible.
Lung cancer patients are invited to register for free tumor whole-genome sequencing and high-coverage germline. In that way, they will not only contribute toward this oncology research but will also gain better treatment choices.
According to the press release, biomedical and healthcare research have transformative potential, especially where large genomic datasets are created and analyzed. However, the obstacles that might limit this potential entail inefficient consent management, slow data generation, and data fragmentation.
Last week, Boehringer Ingelheim, a major pharmaceutical firm, partnered with Solve.Care, blockchain healthcare platform, to develop a diabetes patients’ trusted data sharing network that is powered digital assets and blockchain.
In January, Merck was able to get a patent in the United States. The patent was for the development of a system which fuses blockchain and artificial intelligence to ascertain the authenticity of particular physical objects.
In the last fall, reports came out that Nebula Genomics together other projects were working on various blockchain solutions. The aim was to innovatively develop circulation and ownership models that work on scientifically and sensitive, valuable genomic data.